INmune Bio's unique Alzheimer's trial endpoint receives validation [Yahoo! Finance]
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: Yahoo! Finance
The AD02 trial (NCT05318976), investigating INmune's tumour necrosis factor (TNF) XPro, is using Early Mild Alzheimer's Cognitive Composite (EMACC) as a primary endpoint. EMACC is an objective measure of cognitive function that characterises cognitive changes that occur during the early stages of the neurodegenerative disease. This is assessed by a word list learning test, category fluency test, and digit symbol coding test, amongst others. INmune's vice president of neuroscience CJ Barnum said the company is conducting the first trial with EMACC as a primary endpoint and that this interim analysis was critical to ensure that the EMACC is performing as “intended”. INmune commissioned a third party to evaluate interim data of patients who completed the six-month trial. Following a blinded sample size re-estimation using the primary endpoint, the biotech concluded the trial was appropriately powered. The FDA placed the study in a clinical hold in May 2022 due to manufacturing i
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial [Yahoo! Finance]Yahoo! Finance
- INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease TrialGlobeNewswire
- INmune Bio Inc. to Join Russell 3000® Index [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc. to Join Russell 3000® IndexGlobeNewswire
- The Limitations Of Anti-Inflammatory Drugs For The Treatment Of Alzheimer's Disease [Seeking Alpha]Seeking Alpha
INMB
Sec Filings
- 6/26/24 - Form 4
- 6/13/24 - Form 8-K
- 6/12/24 - Form 4
- INMB's page on the SEC website